KYMR ▲ +5.0% - Kymera Therapeutics, Inc. $KYMR - Kymera Therapeutics to Announce KT-621 BROADEN2 Phase 2b Atopic Dermatitis Trial Results on November 23, 2026 20-NOV-2026 04:01 PM ET